|Awarded On||December 05, 2012|
|Title||Targeting Therapy Resistance using Epithelial to Mesenchymal Transition (EMT) Pathways in Preclinical Claudin Low Breast Cancer Models|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Jeffrey M Rosen|
Even with recent advances in cancer therapies many patients still succumb to metastases due to therapeutic resistance and disease recurrence. Recently, solid tumors were found to contain specific subsets of cancer cells that are comparatively more resistant to conventional treatments and which are thought to be responsible for metastasis and recurrence. We have demonstrated that signaling pathways that regulate an embryonic developmental program, known as epithelial-to-mesenchymal transition (EMT), are reactivated in cancers and that these EMT-regulated pathways promote the generation of therapeutically resistant cells. Moreover, these cells exhibit stem cell properties and have gene signatu...